PFE Quote Spy PFE NEW Message Board  
Click to close X

Visit a stock's Spy page to see who else is tracking it and who else is talking about it. Spy pages also list institutional holders.

Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer’s Disease

PFE  MDVN  

Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - November 03, 08:00AM from (www.businesswire.com)

Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD). The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, the leading AD medication worldwide, on neuropsychiatric

Read the full article

Flag

Please flag this item as:
Close [X]
Spam
Duplicate post
Inappropriate content
Other
Upon clicking, our editors will review the post. Thanks for making tickerspy.com a more informative community.

 
Post your reply
  Log in or register to post a reply.